# GSK.L - GlaxoSmithKline plc

> Fecha: 2026-02-05
> Analista: Claude (Fundamental Analyst Agent)
> Framework: v4.0

---

## TL;DR

GSK es una Big Pharma diversificada (HIV, Vaccines, Oncology) con Quality Score 59 (Tier B). La empresa cotiza near fair value (MoS 6-15% segun metodo), sin margen de seguridad suficiente para Tier B (tipicamente 20-25%). La tesis se complica por: (1) patent cliff de dolutegravir 2027-28, (2) decepcion en vacunas RSV (Arexvy), (3) CEO transition a Luke Miels. El negocio es solido pero el precio actual ya refleja las fortalezas. **WATCHLIST** con entry price 1750-1850p que daria MoS 20%+.

---

## Quality Score: 59/100 → Tier B

| Categoria | Puntos | Comentario |
|-----------|--------|------------|
| **Financial Quality** | 21/40 | ROIC spread bajo (+1.7pp), FCF margin 11.4%, leverage OK (1.2x) |
| **Growth Quality** | 10/25 | Revenue CAGR 6.2% OK, EPS CAGR negativo (-12.8%) por one-offs |
| **Moat Evidence** | 20/25 | GM premium +17.4pp vs sector, posicion #3-5 global |
| **Capital Allocation** | 8/10 | 10+ anos dividendos, insider ownership 2.3% |
| **TOTAL** | **59/100** | **Tier B - Quality Value** |

### Tier Implications
Segun `learning/principles.md` y precedentes en `decisions_log.yaml`:
- Tier B tipicamente requiere MoS 20-25%
- Ejemplos: HRB a 5.7% con MoS 42%
- GSK con MoS 6-15% es insuficiente para el nivel de riesgo

---

## Business Understanding

### Modelo de Negocio

GSK es una farmaceutica global diversificada en tres pilares:

1. **Specialty Medicines (56% revenue)**: HIV (ViiV Healthcare), Oncology, Respiratory, Immunology
2. **Vaccines (26% revenue)**: Shingrix (shingles), Arexvy (RSV), portfolio pediatrico
3. **General Medicines (18% revenue)**: Legacy portfolio, declining

**Problema que resuelve:** Tratamientos para enfermedades cronicas (HIV, cancer) y prevencion (vacunas) en poblacion envejecida global.

**Tipo de ingresos:**
- Specialty: Prescripciones recurrentes (alta predictibilidad)
- Vaccines: Estacional, dependiente de recomendaciones CDC/reguladores
- General: Declive controlado (run-off portfolio)

### Unit Economics

| Metrica | Valor | Comentario |
|---------|-------|------------|
| Gross Margin | 67.4% | +17pp vs sector median, indicativo de moat |
| Operating Margin | 17.7% | Core OP margin 30% (adjusted) |
| FCF Margin | 11.4% | Lower than ideal, improving |
| R&D/Revenue | ~15% | Standard para Big Pharma |
| Payout Ratio | 46% | Sostenible, room for growth |

### Segmentos Clave (2025 Results)

| Segmento | Revenue 2025 | Growth | Key Driver |
|----------|-------------|--------|------------|
| **HIV (ViiV)** | £7.7B | +11% | Dovato +22%, Cabenuva +42% |
| **Oncology** | £2.0B | +43% | Jemperli +89%, Zejula declining |
| **Vaccines** | £8.2B | ~flat | Shingrix -4%, Arexvy -72% in Q3 |
| **Respiratory** | £5.0B | +8% | Nucala, Trelegy growing |
| **Immunology** | £2.8B | +15% | Benlysta franchise |

### Por Que Esta "Barata"

**Narrativa del mercado:**
1. Patent cliff de dolutegravir (2027-28): £5.65B revenue at risk
2. Arexvy (RSV vaccine) decepcion: CDC narrow recommendation, -72% Q3
3. CEO transition: Emma Walmsley -> Luke Miels (Jan 2026)
4. Sector Big Pharma odiado: post-COVID hangover, IRA drug pricing fears

**Mi contra-tesis:**
1. **Patent cliff ya mitigandose**: Cabenuva +42%, long-acting HIV is transition path
2. **Arexvy temporal**: EMA approval 18+ (Feb 2026) expands TAM, peak sales £3B+ intact
3. **Miels es operador fuerte**: Chief Commercial Officer, execution focus
4. **Valuacion modesta**: P/E 15.7x vs peers 17-22x, discount already priced

**Value Trap Checklist:**

| Factor | SI/NO | Comentario |
|--------|-------|------------|
| Industria en declive secular | NO | Pharma growing 6% CAGR |
| Disrupcion tecnologica | NO | AI helps R&D, not displaces |
| Management destruyendo valor | NO | £2B buyback, M&A disciplined |
| Balance deteriorandose | NO | Net debt/EBITDA 1.2x, manageable |
| Insider selling masivo | NO | CEO sold normal vesting amounts |
| Dividend cut reciente | NO | +5% YoY |
| Perdida market share | MAYBE | Vaccines losing, HIV gaining |
| ROIC < WACC | NO | ROIC 8-17% vs WACC ~7% |
| FCF negativo | NO | £3.6B+ FCF |
| Goodwill >50% equity | NO | ~35% |

**Score: 1/10** → No es value trap, pero no es bargain

---

## Projecciones (Derivadas, no Defaults)

### Revenue Growth

| Factor | Estimacion | Razonamiento |
|--------|-----------|--------------|
| TAM Pharma Growth | +5% | Global pharma 6% CAGR, GSK mix-adjusted |
| Market Share | ~flat | Gaining in HIV/Oncology, losing vaccines |
| Pricing | +1% | IRA limits pricing power, offset by mix |
| **Total Revenue Growth** | **+3-5%** | Consistent with 2026 guidance |

### Margin Trajectory

- **Gross Margin**: Stable 67-68% (product mix improving)
- **Operating Margin**: Core 30% -> 32% by 2028 (scale + efficiency)
- **FCF Conversion**: 70-75% of Net Income (capex declining post-investment cycle)

### WACC Derivado

| Component | Value | Source |
|-----------|-------|--------|
| Risk-free Rate | 3.8% | UK 10Y Gilt |
| Equity Risk Premium | 5.0% | Standard |
| Beta | 0.65 | Estimated (defensive pharma) |
| Cost of Equity | 7.1% | Rf + Beta*ERP |
| Cost of Debt (after-tax) | 3.5% | Effective rate |
| D/V | 13% | Net debt / EV |
| E/V | 87% | Equity / EV |
| **WACC** | **6.6%** | Weighted average |

### Escenarios

| Scenario | Prob | Revenue Growth | Margin | FV (pence) |
|----------|------|----------------|--------|------------|
| **Bear** | 25% | 2% | 28% Core OP | 1800p |
| **Base** | 50% | 4% | 30% Core OP | 2300p |
| **Bull** | 25% | 6% | 32% Core OP | 2800p |

**Asunciones Bear:**
- Dolutegravir erosion faster than expected
- Arexvy fails to recover
- Oncology launches disappoint

**Asunciones Bull:**
- Cabenuva/long-acting HIV captures transition
- Arexvy EMA 18+ approval drives reacceleration
- Blenrep becomes blockbuster
- M&A adds growth

---

## Valoracion

### Metodo 1: EV/EBIT (60% peso)

| Metrica | Valor |
|---------|-------|
| Core Operating Profit 2025 | £9.78B |
| Fair Multiple | 11x (vs peers 10-15x) |
| Enterprise Value | £107.6B |
| Net Debt | £13.3B |
| Equity Value | £94.3B |
| Shares | 4.04B |
| **Fair Value** | **2334p** |

**Razonamiento del multiplo:**
- 11x es conservador vs PFE (10x, peor position) y MRK (14x, Keytruda premium)
- Descuenta patent cliff pero reconoce pipeline progress
- Coherente con precedente: NVO at 13x durante crisis (Tier A), GSK at 11x (Tier B)

### Metodo 2: P/E Forward (40% peso)

| Metrica | Valor |
|---------|-------|
| Forward EPS 2026 | 197p (implied from 11x) |
| Fair Multiple | 13x (vs peers 17-22x) |
| **Fair Value** | **2561p** |

**Razonamiento del multiplo:**
- GSK trading at discount vs all peers
- 13x conservative, not demanding growth premium
- Dividend support provides floor

### Weighted Fair Value

| Metodo | FV | Peso | Weighted |
|--------|-----|------|----------|
| EV/EBIT 11x | 2334p | 60% | 1400p |
| P/E 13x | 2561p | 40% | 1024p |
| **Weighted Average** | | **100%** | **2424p** |

### Margin of Safety

| Metrica | Valor |
|---------|-------|
| Current Price | 2180p |
| Fair Value (Weighted) | 2424p |
| **MoS vs Base** | **10%** |
| **MoS vs Bear (1800p)** | **-21%** |

---

## Escenarios con Probabilidades

| Scenario | FV | Prob | Weighted |
|----------|-----|------|----------|
| Bear | 1800p | 25% | 450p |
| Base | 2300p | 50% | 1150p |
| Bull | 2800p | 25% | 700p |
| **Expected Value** | | | **2300p** |

MoS vs Expected Value: **5.2%**

---

## Comparacion con Posiciones Actuales en Pharma

| Ticker | QS | Tier | Position | MoS at Entry | Status |
|--------|-----|------|----------|--------------|--------|
| PFE | ~55 | B | Activa | ~30% | HOLD - transition |
| SAN.PA | ~60 | B | Activa | ~25% | HOLD - growing |
| **GSK.L** | **59** | **B** | **N/A** | **10%** | **Insufficient MoS** |

GSK no mejora la diversificacion significativamente:
- Ya tenemos exposicion UK (4 posiciones)
- Ya tenemos exposicion pharma (PFE, SAN.PA, NVO)
- MoS inferior a lo que ya tenemos

---

## Kill Conditions

1. **Dolutegravir erosion >30% in year 1 post-patent** (vs expected 15-20%)
2. **FCF < £3.0B** (currently £3.6B, indicates fundamental deterioration)
3. **Dividend cut** (would indicate management losing confidence)
4. **Oncology pipeline failure** (Blenrep or Jemperli significant miss)
5. **New CEO (Miels) materially changes capital allocation** (abandons buybacks, excessive M&A)

---

## Catalizadores

| Catalizador | Timeline | Prob | Impacto |
|-------------|----------|------|---------|
| Arexvy EMA 18+ approval | Feb 2026 | 85% | Medium (+5-10%) |
| Dolutegravir patent clarity | 2027 | 90% | Negative priced in |
| Blenrep launch traction | 2026 | 60% | Medium |
| HIV long-acting adoption | 2026-27 | 70% | High |
| Sector re-rating | 12-24m | 40% | High |

---

## Veredicto: WATCHLIST

### Razonamiento (Framework v4.0)

Aplicando `learning/principles.md`:

1. **Principio 5 (QS como Input):** QS 59 (Tier B) indica riesgo moderado. MoS 10% es insuficiente para compensar patent cliff uncertainty.

2. **Principio 7 (Consistencia por Razonamiento):** Precedentes en `decisions_log.yaml`:
   - HRB (Tier B, QS 73) comprada con MoS 42%
   - GSK (Tier B, QS 59) con MoS 10% es inconsistente

3. **Principio 1 (Sizing por Conviccion):** Mi conviccion es MEDIA:
   - Negocio solido pero no excepcional
   - Patent cliff es riesgo real (no ya descontado completamente)
   - CEO transition adds uncertainty

4. **Principio 3 (Diversificacion Sectorial):** Ya tenemos 3 posiciones pharma (PFE, SAN.PA, NVO). Anadir GSK aumenta concentracion sectorial sin mejorar quality.

### Entry Price Recomendado

Para MoS 20% (minimo para Tier B):
- Fair Value: 2424p
- Entry Price: **1940p** o inferior

Para MoS 25% (mas conservador):
- Entry Price: **1820p** o inferior

### Probabilidad de Alcanzar Entry

- GSK ha estado en 1750-1800p range en Q3 2024
- 52-week low: 1242p (extreme pessimism)
- Probable trigger: Sector weakness, earnings miss, o general market correction

---

## Standing Order (si WATCHLIST aprobado)

```yaml
ticker: GSK.L
action: BUY
trigger_price: 1850p
position_size: 3% (Tier B, pharma exposure already high)
expiry: 2026-06-30
conditions:
  - Q1 2026 results not materially worse than guidance
  - No dividend cut announced
  - No major pipeline failures
```

---

## META-REFLECTION

### Incertidumbres/Dudas
1. **ROIC divergencia entre fuentes**: Vi ROIC desde 8% hasta 17% dependiendo de la metodologia. Use 8% (GuruFocus TTM) para ser conservador, pero esto afecta el QS score.
2. **Core vs GAAP earnings**: GSK reporta "core" earnings excluyendo one-offs. Mi valoracion usa core OP, pero GAAP earnings son mucho menores (£2.6B vs £9.8B core OP). Esto podria subestimar riesgo.
3. **Arexvy recovery timing**: CDC guidelines unlikely to change 2025-26. Recovery depende de EMA y ex-US markets. Timeline incierto.

### Sugerencias para el Sistema
1. **Crear tool para comparacion peer P/E y EV/EBIT automatizada**: Tuve que hacer manualmente, error-prone.
2. **Anadir "sector concentration warning" en constraint_checker**: Ya tenemos 3 pharma positions, deberia flag esto.

### Preguntas para Orchestrator
1. ¿La exposicion pharma actual (PFE + SAN.PA + NVO) justifica anadir GSK incluso con MoS suficiente? Hay argumento para diversificar DENTRO del sector, pero tambien hay argumento para no sobreconcentrar.

### Anomalias Detectadas
1. **EPS CAGR -12.8%**: Esto parece reflejar one-offs (COVID unwind, restructuring). Core EPS ha crecido. El QS penaliza por GAAP EPS, pero quiza deberia ajustarse.

---

## Sources

- [GSK Q4 2025 Results](https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-2025-performance-and-re-affirms-long-term-outlooks/)
- [GSK Analyst Consensus](https://www.gsk.com/en-gb/investors/analyst-consensus/)
- [Patent Cliff Analysis - GEN News](https://www.genengnews.com/topics/drug-discovery/top-20-drugs-heading-for-the-patent-cliff-2026-2029/)
- [ViiV Healthcare HIV Portfolio](https://viivhealthcare.com/)
- [GSK Dividend History - Stock Analysis](https://stockanalysis.com/stocks/gsk/dividend/)
- [GSK 2026 Outlook - Syneticx](https://www.syneticx.com/blog/gsk.html)
- [BioPharma Dive - Vaccine Sales](https://www.biopharmadive.com/news/gsk-vaccines-sales-arexvy-rsv-third-quarter-earnings/731474/)
- [GSK Oncology Portfolio](https://www.pharmaceutical-technology.com/news/gsk-fy2025-financial-results-hiv-oncology/)

---

**Framework Version:** 4.0
**Ultima actualizacion:** 2026-02-05
